Hims & Hers (HIMS) extended its rally this week, surging for a second straight session as investors reacted to signals that U.S. regulators may take a more flexible approach toward certain peptide treatments. This marks a shift in sentiment for the telehealth company, which has been under pressure for much of the year due to regulatory uncertainty.
The gains come after comments from Health Secretary Robert F. Kennedy Jr. indicating that the Food and Drug Administration will reevaluate restrictions on several peptides, a development that could materially expand Hims & Hers’ addressable market if policies shift in the company’s favor.
FDA Review Sparks Optimism Around Peptides
At the heart of the rally is a planned FDA review of multiple peptide substances currently restricted under “Category 2,” a designation used for compounds considered too risky or insufficiently studied for compounding. Regulators are expected to begin evaluating these peptides in upcoming advisory committee meetings, where independent experts will assess their safety and clinical value. For investors, the key takeaway is that substances previously off-limits could eventually become accessible through regulated channels. This shift is being interpreted as an early step toward loosening oversight, potentially allowing telehealth platforms like Hims & Hers to broaden their treatment offerings.
Why Peptides Matter for Hims & Hers
Hims & Hers has been actively investing in peptide-related treatments, including acquiring a manufacturing facility to support compounded therapies. These products span categories like weight loss, muscle recovery, and overall wellness, all fast-growing segments within digital health. If regulatory barriers ease, the company could scale these offerings more aggressively, tapping into strong consumer demand for personalized and accessible care options delivered online. Analysts note that peptides represent a meaningful growth lever, particularly as patients increasingly seek alternatives to traditional healthcare channels.
GLP-1 Strategy Adds Another Layer
The company’s positioning in the booming weight-loss drug market is also evolving. Hims & Hers recently struck a collaboration with Novo Nordisk, one of the leading players behind GLP-1 medications. The partnership allows Hims & Hers to offer access to FDA-approved treatments while also exploring the limited use of compounded alternatives. This hybrid approach helps the company stay compliant while still participating in one of the fastest-growing areas in healthcare. Importantly, Novo Nordisk also dropped a prior patent dispute with the company, removing a legal overhang that had weighed on the stock.
Regulatory Overhang Hasn’t Fully Cleared
Despite the recent rally, Hims & Hers shares remain significantly below earlier highs, reflecting ongoing concerns about regulatory risk. The FDA has been tightening scrutiny around compounded drugs, particularly in the GLP-1 category, where safety, efficacy, and intellectual property issues remain front and center. Any unfavorable rulings from upcoming reviews could quickly reverse recent gains. Additionally, even if some peptides are approved for broader use, the timeline for commercialization and scaling remains uncertain.
Looking Ahead
Hims & Hers is at a pivotal moment, with regulatory developments poised to shape its next phase of growth. The FDA’s willingness to revisit peptide restrictions has injected fresh optimism into the stock, but the path forward is far from guaranteed. Investors will be watching closely as advisory committee reviews unfold in the coming months. If outcomes are favorable, Hims & Hers could unlock a powerful new growth engine, but until then, the stock is likely to remain sensitive to policy signals and headline risk.